Global and United States Male Hypogonadism Therapy Market Report & Forecast 2022-2028

Male hypogonadism, also known as testosterone deficiency, is a failure of the testes to produce the male sex hormone testosterone, sperm, or both. It can be due to a testicular disorder or the result of a disease process involving the hypothalamus and pituitary gland.
Market Analysis and Insights: Global and United States Male Hypogonadism Therapy Market
This report focuses on global and United States Male Hypogonadism Therapy market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Male Hypogonadism Therapy market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, Parenteral accounting for % of the Male Hypogonadism Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Male Hypogonadism Therapy market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Male Hypogonadism Therapy Scope and Market Size
Male Hypogonadism Therapy market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Male Hypogonadism Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Male Hypogonadism Therapy market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Parenteral
Transdermal
Oral
Others
Segment by Application
Hospitals
Drugstores
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Eli Lilly
Pfizer
AbbVie
Novo Nordisk
Merck KGaA
Mylan
Bayer
Teva
Novartis
Abbott
Roche
Endo International
Ipsen
ANI Pharmaceuticals
TherapeuticsMD